-
Product Insights
Sicca Syndrome (Sjogren): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2026" provides an overview of Sicca Syndrome (Sjogren) Clinical trials scenario. This report provides top line data relating to the clinical trials on Sicca Syndrome (Sjogren). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Amyotrophic Lateral Sclerosis (ALS): Epidemiology Report and Forecast to 2035
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a neurodegenerative disorder that affects the motor neurons in the brain and spinal cord responsible for voluntary muscle movement and breathing (National Institute of Neurological Disorders and Stroke, 2026). ALS typically manifests as either weakness in the limbs (spinal onset) or difficulty in speaking or swallowing (bulbar onset) (Longinetti & Fang, 2019). Eventually, people with ALS lose their ability to stand or walk, the use of their hands and...
-
Sector Analysis
Dyslipidemia: Epidemiology Report and Forecast to 2035
Dyslipidemia is a medical condition characterized by abnormal lipid levels in the bloodstream, and includes the imbalance of cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C) (Pappan, Awosika and Rehman, 2024; Roland, 2026). Dyslipidemia increases the risk of cardiovascular disease (CVD), and has been associated with multiple diseases, including type 2 diabetes (T2D), neurodegenerative diseases, and cancer (Zhu et al., 2024). Dyslipidemia is classified into primary dyslipidemia and secondary dyslipidemia. Primary dyslipidemia refers to dyslipidemia caused...
-
Thematic Analysis
Rare Diseases: Innovation, Investment, and Unmet Needs - Strategic Intelligence
Why Does the Rare Disease Market Matter? The rare disease market represents a significant but structurally underserved opportunity for pharmaceutical and biotechnology companies. Drug development activity is expanding across therapy areas, indications and modalities, while companies are increasingly using mergers and acquisitions (M&A) and licensing agreements to strengthen their portfolios and build capabilities. However, development activity remains uneven. Oncology accounts for a substantial share of rare disease pipeline activity but is also the least mature area of the pipeline. At...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, August 2026
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Sector Analysis
Small-Cell Lung Cancer (SCLC): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Small-Cell Lung Cancer (SCLC) Therapeutics. - In 2025, there were 232,630 diagnosed prevalent cases of SCLC in the 16 countries covered in GlobalData’s epidemiology forecast. - Over the past decades, the SCLC treatment landscape was dominated by Etoposide and Platinum (EP), with few and only modestly effective relapse treatments and minimal therapeutic differentiation. Currently, adding PD‑L1 inhibitors to chemotherapy is the standard first-line approach in Extensive...
-
Sector Analysis
Hodgkin Lymphoma: Epidemiology Report and Forecast to 2035
Hodgkin lymphoma (HL) is a type of lymphoma, a cancerous condition that affects the lymphatic system and occurs in both children and adults. HL is a rare disease that starts with abnormal growth of the white blood cells, called lymphocytes, and then spreads beyond the lymphatic system and impairs the body’s immune system. The exact cause of HL is unclear; however, 20–40% of HL cases had a prior diagnosis of infectious mononucleosis caused by the Epstein-Barr virus (EBV). HL originates...
-
Sector Analysis
Glioblastoma (GBM): Epidemiology Report and Forecast to 2035
Glioblastoma multiforme (GBM) is a highly aggressive form of glioma, a cancer arising from astrocytes, and is the most common type of brain tumor in adults (Kanderi et al., 2024). The distinction of “multiforme” comes from the wide range of genetic expressions characteristic of the cancer, complicating treatment (Kanderi et al., 2024). Glioblastoma multiforme is currently incurable, with a median survival time of 15 months and a 7.2% five-year survival rate (Kanderi et al., 2024). Gold standard treatment is a...
-
Sector Analysis
Narcolepsy Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7 major markets and provides an Excel-based forecast model for the narcolepsy market through 2035 The narcolepsy therapeutics market totaled $4.6 billion in 2025 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan). It is projected to grow rapidly at 5.5% compound annual growth rate (CAGR) to $7.8 billion by 2035, mainly driven by the entry of orexin agonists from the late-stage pipeline, the introduction of new formulations, and...
-
Sector Analysis
Narcolepsy: Epidemiology Report and Forecast to 2035
Narcolepsy is a chronic neurological disorder that affects the brain’s ability to control sleep-wake cycles, making people very sleepy during the day (Mayo Clinic, 2024; National Institute of Neurological Disorders and Stroke, 2026). Some patients also have other symptoms, such as muscle weakness when they feel strong emotions, which is known as cataplexy. Narcolepsy can disrupt daily life, making it hard to work, study, or maintain relationships. Narcolepsy is an uncommon but manageable lifelong condition (Cleveland Clinic, 2025). There are...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.